In patients with congestive heart failure, 3 months of beta-blocker therapy significantly reduced lipid peroxidation, while ACE inhibitor therapy significantly reduced von Willebrand factor levels.
Do beta-blockers and ACE inhibitors improve markers of oxidative stress and endothelial damage in patients with congestive heart failure?
Beta-blockers, but not ACE inhibitors, reduce lipid peroxidation in patients with congestive heart failure, suggesting differential effects on oxidative stress.
BACKGROUND: Chronic elevation of plasma catecholamines and sympathetic stimulation in chronic heart failure (CHF) leads to increased production of free radicals, and so possibly to endothelial damage/dysfunction and atheroma formation. Abnormal oxidative stress may therefore be related to some of the high mortality and morbidity in CHF. The objective of the present prospective open study was to compare the effects of beta-blockers and ACE inhibitors in relation to oxidative stress and endothelial damage in CHF. METHODS: We studied 66 outpatients with CHF: 46 patients were established on an ACE inhibitor and were then started on a beta-blocker, and 20 patients not previously on ACE-inhibitors were started on lisinopril. Baseline levels of the measured parameters were compared to 22 healthy control subjects. Serum lipid hydroperoxides (LHP) and total antioxidant capacity (TAC) were determined as indices of oxidative damage and antioxidant defence, and plasma von Willebrand factor (vWf) as an index of endothelial damage/dysfunction. RESULTS: Baseline indices for the measures of oxidative damage and endothelial function in the 66 CHF patients were significantly higher than healthy control subjects median LHP 7.5 (5.9-12.6) vs. 4.8 micromol/l, P=0.0022; TAC 428 (365-567) vs. 336 Trollox Eq. Units, P=0.0005; mean vWf 134+/-27 vs. 89+/-23 IU/dl, P<0.0001. Following 3 months of maintenance therapy with beta-blockers, there was significant reduction in LHP levels, but not TAC or vWf. ACE inhibitor therapy also significantly reduced vWf levels, but failed to have any statistically significant effects on LHP or TAC. CONCLUSION: This pilot study suggests that oxidative stress in CHF may be due to increased free radical production or inefficient free radical clearance by scavengers. beta-Blockers, but not ACE inhibitors, reduced lipid peroxidation in patients with CHF. No relation was demonstrated between a reduction in oxidative damage and endothelial damage/dysfunction.
Chin et al. (Sat,) conducted a other in Congestive Heart Failure (n=88). Beta-blockers and ACE inhibitors vs. Baseline / Healthy controls was evaluated on Serum lipid hydroperoxides (LHP), total antioxidant capacity (TAC), and plasma von Willebrand factor (vWf). In patients with congestive heart failure, 3 months of beta-blocker therapy significantly reduced lipid peroxidation, while ACE inhibitor therapy significantly reduced von Willebrand factor levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: